Sanofi (SNW) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Sanofi DE:SNW is currently developing the following drugs: Balinatunfib, Sar446597, Sham Comparator, Lunsekimig, Rilzabrutinib, Glucocorticoid, Duvakitug, Sar445229, Menacyw Conjugate Vaccine, Menac Conjugate Vaccine, Belumosudil, Dupilumab, Nirsevimab, Teplizumab, Rilzabrutinib, Rsv Vaccine Formulation 1 Dose, Rsv Vaccine Formulation 2 Dose, Rsv Vaccine Formulation 3 Dose, Rsv Vaccine Formulation 4 Dose, Rsv Vaccine Formulation 5 Dose, Rsv Vaccine Formulation 6 Dose, Rsv Vaccine Formulation 7 Dose, Rsv Vaccine Formulation 8 Dose, Yellow Fever Vaccine (Live), Measles, Combinations With Mumps And Rubella, Live Attenuated, Yellow Fever Vaccine (Live), Yf Vaccine (Live), Rilzabrutinib Dose 1, Rilzabrutinib Dose 2, PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine, M-M-RvaxPro vaccine, Varivax vaccine, SAR442970, Olipudase Alfa, Efanesoctocog Alfa, Lunsekimig, Mometasone Furoate Nasal Spray (Mfns), Pandemic Flu H5 Ha Mrna Sd2 Vaccine, Chlamydia Mrna Vaccine, Sar441566, Riliprubart Prefilled Pen (Pfp), Sar446268, Itepekimab (Sar440340), Mometasone Furoate Nasal Spray (Mfns), Tiv-Ha Vaccine Formulation 1 At Low Dose, Tiv-Ha Formulation 1 At High Dose, Tiv-Ha Formulation 2 At Low Dose, Tiv-Ha Formulation 2 At High Dose, Rsv/Hmpv/Piv3 Formulation 2 At Low Dose, Rsv/Hmpv/Piv3 Formulation 1 At High Dose, Rsv/Hmpv/Piv3 Formulation 2 At High Dose, Rsv/Hmpv/Piv3 Formulation 1 At Low Dose, Riv4 (Supemtek®), PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix. These drug candidates are in various stages of clinical development as the company works toward FDA approval.